Stay updated with breaking news from Lead Asset. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TG Therapeutics (NASDAQ:TGTX) concluded its most recent trading session with a closing price of $10.25, showcasing a remarkable 56.9% increase since the stock’s October low of $6.53. This stock was on quite a roll last week, surging by a staggering 65.6%. What’s fuelling this impressive growth? The company has seen triple-digit sales and earnings per […]
/PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop,...
/PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...
Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING...
Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotech industry. See why investors should consider IMAB.